**7. Prognosis**

Good prognosis in patients diagnosed with tuberculous pericarditis requires early recognition and initiation of treatment. However, it is still associated with high mortality, reaching 17–40% [6]. The most important treatments are antituberculous drugs and corticosteroids. The goal of preventing pericardial fibrosis and constrictive pericarditis is of importance. Surgical pericardiectomy due to constrictive pericarditis is associated with perioperative mortality, depending on the centre, reaching 2.3–12% [51,52]. In the future, hopes are associated with intrapericardial fibrinolysis, which is currently under investigation in the Second Investigation of the Management of Pericarditis (IMPI-2) Trial (https://clinicaltrials.gov/ct2/show/ (accessed on 20 May 2018) NCT02673879). The rationale for its use is based on its theoretical ability to break up loculated fibrin strands, allowing for the complete evacuation of the pericardium and a reduction in mediators of fibrosis [2,53].

**Author Contributions:** Conceptualization, M.S. and M.D.; methodology, M.D.; software, M.D.; validation, E.A.-K. and M.K.; formal analysis, M.D. and M.S.; investigation, J.G.; resources, M.D.; data curation, M.D.; writing—original draft preparation, M.D. and M.S.; writing—review and editing, M.S., M.D., K.B., J.G., M.K., E.A.-K. and W.T.; visualization, K.B.; supervision, W.T. and E.A.-K.; project administration, M.D. and M.S.; funding acquisition, not applicable. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Data Availability Statement:** Data supporting reported results can be found in source data collected in National Tuberculosis and Lung Diseases Research Institute.

**Conflicts of Interest:** The authors declare no conflict of interest.
